Lock-Release Technology.

Pure Passion.

GenoClone Bio-Medical Ltd’s proprietary Lock-Release technology is a fast, simple, cost efficient and robust system to guarantee GenoClones of a consistently high quality and purity.

UNLOCKING ADC POTENTIAL.

Lock-Release is the only commercially available system that controls aggregation at source, is scaleable and capable of meeting GMP regulatory requirements required to produce materials for use in human clinical trials.

  • Effective aggregation control platform.
  • A new paradigm in the way GenoClones are developed & manufactured.
  • Eliminates process steps.
  • Approaches the market from a different direction.
  • Increasing accessibility, efficacy & quality of life for patients.

The Lock-Release Process.

LOCK-RELEASE TECHNOLOGY.

COMMERCIAL ADVANTAGES.

Lock-Release technology prevents overlooking quality candidates due to critical aggregation control problems.

EMPOWERING DEVELOPMENT.

  • Enables product development for successful clinical testing.
  • An economically viable process.
  • Addresses a major challenge in the ADC manufacturing pipeline.
  • Opens up commercialisation for promising candidates.
  • Fewer failures and delays.

COST-EFFECTIVE MANUFACTURING.

  • Provides a simple and robust technique for producing GenoClones.
  • Far superior in terms of early ADC screening.
  • Guarantees GenoClones free of residuals (particularly cytotoxic payloads and solvents).
  • Significantly simplifies ADC manufacturing process.

RELATED NEWS

IN DEVELOPMENT.

A NEW DOWNSTREAM
BIO-CONJUGATION PROCESS.

Advanced manufacturing paradigm to save 25% of total costs and
Specialist Process Innovation Group created to validate approach.

HOW CAN WE HELP YOU?
GET IN TOUCH